Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Gustav Fischer (1901)
E N D Presentation Transcript GLP-1 Agonists and Cardiovascular Health Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM Part 2 of 2 Change in Triglycerides and HDL-C as Function of Weight-Change Quartile at 82 Weeks Effects of GLP-1 agonists on inflammatory markers GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) E-selectin was not significantly reduced C-reactive protein has also been associated with increased cardiovascular disease Patients treated with exenatide showed marked decrease in c-reactive protein levels after an 82-week study (from 3.21mg/dL to 1.35 mg/dL) Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbAlc, and body weight in patients with type 2 diabetes mellitus
enda hvers tma
It boosts the development of bacteria that generate short-chain fatty acids (SCFAs) in the gut of people with T2DM, leading to an increase in SCFAs levels in the colon, ultimately improving host metabolism (Forslund et al., 2015
US$ 22.79
US$ 24.17
US$ 24.48
US$ 21.99
US$ 29.09
US$ 21.92
US$ 20.81
US$ 21.64
US$ 28.34
